Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

Edgewise Therapeutics (Nasdaq: EWTX) will present new clinical and natural history data on sevasemten for Becker muscular dystrophy at the 2026 MDA Clinical and Scientific Conference in Orlando, March 8–11, 2026.

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) will present new clinical and natural history data on sevasemten for Becker muscular dystrophy at the 2026 MDA Clinical and Scientific Conference in Orlando, March 8–11, 2026.

Edgewise will host a lunch forum on March 9 and showcase multiple scientific posters from March 8–10, including MESA open-label extension results and CANYON cardiac biomarker analyses. Presentations will be posted on the company website after the conference.

Argus Mar 3 session

-3.00% close to close Open Argus

Details

News Market Reaction – EWTX

On Mar 3, the day this news came out, EWTX closed 3.00% below the previous close.

Data tracked by StockTitan Argus for the Mar 3 session.

Key Figures

Functional follow-up: Up to 3.5 years MDA 2026 dates: March 8–11, 2026 Lunch forum date: March 9, 2026, noon ET +5 more

Functional follow-up

Up to 3.5 years

MESA open-label extension functional stabilization in Becker

MDA 2026 dates

March 8–11, 2026

Muscular Dystrophy Association Clinical and Scientific Conference timing

Lunch forum date

March 9, 2026, noon ET

Edgewise Becker-focused lunch forum at MDA 2026

Cash position

$530.1 million

Cash, cash equivalents and marketable securities as of Dec 31, 2025 (8-K)

Q4 2025 net loss

$50.2 million

Fourth-quarter 2025 net loss reported in 8-K

Shares outstanding

107,270,521 shares

Common shares outstanding as of Feb 19, 2026 (10-K)

Institutional holding

6,541,210 shares (6.2%)

Paradigm BioCapital beneficial ownership as of Dec 31, 2025

52-week range

$10.60 – $31.82

Pre-news 52-week low and high for EWTX

Historical Context

5 past events · Latest: Mar 02

5 events

1. Mar 02

   Inducement grants

   24h Move

   -2.4%

   Disclosed option grants for 51,000 shares to new non-executive employees.

2. Feb 26

   Earnings update

   24h Move

   -1.5%

   Reported Q4 and 2025 results with strong cash and clear sevasemten NDA timeline.

3. Feb 05

   Conference appearance

   24h Move

   -4.5%

   Announced COO presentation at Guggenheim Biotech Summit with webcast access.

4. Feb 02

   Inducement grants

   24h Move

   +2.6%

   Announced option grants for 198,250 shares under 2024 Inducement Equity Plan.

5. Jan 13

   Corporate update

   24h Move

   +3.4%

   Outlined 2026 milestones, GRAND CANYON enrollment completion and key cardiology readouts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

open-label extension, becker muscular dystrophy, lvef, nt-probnp, +2 more

6 terms

open-label extension medical

"New sevasemten data in Becker will also be presented... including from the MESA open-label extension trial."

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

becker muscular dystrophy medical

"for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical..."

A genetic muscle disorder that causes progressive weakness and tissue loss because the dystrophin protein is reduced or abnormal, typically affecting males with a wide range of severity. For investors, it matters because the condition defines a small, well-characterized patient group and a clear biological target, which shapes clinical trial design, regulatory incentives and the potential market for specialized therapies or diagnostics—think of it as a known structural defect companies can aim to fix.

lvef medical

"Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy..."

Left ventricular ejection fraction (LVEF) is a percentage that measures how much blood the heart’s main pumping chamber pushes out with each beat, like the share of water a pump empties from a bucket each cycle. Investors watch LVEF because it’s a key medical yardstick used to diagnose and track heart function, shaping demand for drugs, devices, clinical trials, insurance costs and the financial outlook of healthcare-related businesses.

nt-probnp medical

"Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy..."

A blood test marker released when the heart is under strain; higher NT‑proBNP levels indicate the heart is working harder or may be failing, similar to a dashboard warning light that signals engine stress. Investors watch NT‑proBNP because changes in the marker can drive clinical trial results, treatment approvals, hospital use, and insurance decisions for heart drugs and devices, all of which affect revenue, adoption and valuation in healthcare companies.

bmd medical

"Female carriers of BMD and DMD mutations show elevated muscle injury proteins..."

Bone mineral density (BMD) is a medical measure of how much mineral — mainly calcium — is packed into a specific volume of bone, often reported as a number from a scan. Investors care because changes in BMD are common primary endpoints for drugs and devices treating osteoporosis and bone disorders; stronger effects on BMD can signal higher chances of regulatory approval, broader market use, and bigger revenue potential. Think of it as a method for checking how solid a building’s concrete is.

dmd medical

"Female carriers of BMD and DMD mutations show elevated muscle injury proteins..."

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes progressive weakening of muscles, typically beginning in childhood, due to the absence of a critical muscle protein. For investors, DMD is important because it represents a well-defined patient population and a high unmet medical need, meaning successful therapies can command significant market value and influence regulatory decisions, trial design and long-term revenue potential—much like a niche product that fills a clear gap in demand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The Company will host a lunch forum with experts presenting Becker natural history data and discussing the need for community and definition of care. New sevasemten data in Becker will also be presented at the conference including from the MESA open-label extension trial. The conference will take place at the Hilton Orlando in Orlando, Fla., from March 8–11, 2026.

Details of the Edgewise forum and scientific posters at MDA:

Edgewise Lunch Forum Highlighting Becker Natural History, Community Progress, and Multi-Disciplinary Care with Neuromuscular Disease Experts

Date: Monday, March 9, 2026, at noon ET

Title: Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care

Presenters:

• Matthew Wicklund, M.D., FAAN, Professor of Neurology, Vice Chair for Research, Department of Neurology, UT Health San Antonio
• Abby Bronson, M.B.A., Vice President, Patient Advocacy and External Innovation, Edgewise
• Amit Sachdev, M.D., M.S., Associate Chief Medical Officer, MSU Healthcare, Medical Director, Department of Neurology and Assistant Professor, Neuromuscular Medicine, Michigan State University

Moderator: Roxana Donisa Dreghici, M.D., Vice President, Clinical Development, Edgewise

Only conference attendees can register for the forum.

Scientific Posters

Title: Long-term stabilization of function in Becker: Sevasemten prevented functional decline up to 3.5 years in MESA open-label extension (477LB)
Presenter: Craig M. McDonald, M.D., Distinguished Professor and Chair at the UC Davis Health Department of Physical Medicine and Rehabilitation, and a Principal Investigator in CANYON and GRAND CANYON
Date: Tuesday, March 10, 2026

Title: Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in CANYON (470LB)
Presenter: Ben Barthel, Ph.D., Edgewise
Date: Monday, March 9, 2026

Title: Patient-focused drug development: Understanding the patient experience and meaningful treatment outcomes in Becker muscular dystrophy via interviews (8S)
Presenter: Abby Bronson, Edgewise
Date: Sunday, March 8, 2026

Title: Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration (167M)
Presenter: Luuli Tran, Ph.D., Edgewise
Date: Monday, March 9, 2026

Posters will be showcased at various times throughout the day in the Exhibit Hall. The full MDA 2026 Conference program is available at mdaconference.org.

The Edgewise presentation and posters will be available on the Edgewise website following the presentations.

About Sevasemten
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. Sevasemten presents a novel mechanism of action designed to selectively limit the exaggerated muscle damage caused by the absence or loss of functional dystrophin. Sevasemten has achieved notable regulatory milestones by securing FDA Orphan Drug Designation for the treatment of Becker and Duchenne, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designations for the treatment of Becker and Duchenne. Further, sevasemten secured the EMA Orphan Drug Designations for the treatment of Becker and Duchenne.

For more information on Edgewise's clinical trials, visit the Company's website.

About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-on-sevasemten-for-the-treatment-of-becker-muscular-dystrophy-at-the-2026-mda-clinical-and-scientific-conference-302701734.html

SOURCE Edgewise Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Edgewise (EWTX) present sevasemten data at the 2026 MDA Conference?

Edgewise will present at the MDA Conference in Orlando from March 8–11, 2026, with sessions on March 9–10. According to the company, presentations include a March 9 lunch forum and multiple scientific posters shown March 8–10, with materials later posted on the company website.

What topics will the Edgewise lunch forum cover about Becker muscular dystrophy (EWTX)?

The forum will cover Becker natural history, community progress, and multidisciplinary care on March 9 at noon ET. According to the company, expert speakers will discuss Becker outcomes, community engagement, and care definition during the lunch forum.

Which sevasemten clinical findings will Edgewise (EWTX) present from MESA and CANYON?

Edgewise will present long-term MESA open-label extension stabilization and CANYON cardiac biomarker effects. According to the company, posters report sevasemten preventing functional decline up to 3.5 years in MESA and LVEF/NT-proBNP analyses from CANYON.

Who are the named presenters for Edgewise (EWTX) at the MDA 2026 meetings?

Presenters include Matthew Wicklund, Craig McDonald, Ben Barthel, Abby Bronson, Luuli Tran, and Edgewise clinical leaders. According to the company, these investigators and Edgewise staff will lead the lunch forum and poster presentations.

Can non-attendees access Edgewise (EWTX) presentation materials from the MDA 2026 Conference?

Yes, Edgewise will make presentations and posters available on its website after the conference. According to the company, materials shown at MDA will be posted on the Edgewise website following the in-person presentations.

Is registration required to attend the Edgewise lunch forum at the MDA Conference on March 9, 2026?

Yes, only conference attendees may register for the Edgewise lunch forum on March 9 at noon ET. According to the company, the lunch forum is restricted to registered MDA Conference participants and requires onsite registration.